Alk­er­mes' $194M pay­ment from Janssen gets ap­proval from court

A New York court has ap­proved John­son & John­son’s Janssen pay­ing Alk­er­mes $194 mil­lion in its ar­bi­tra­tion case.

The case comes from two li­cense agree­ments con­cern­ing Alk­er­mes’ nanopar­ti­cle tech­nol­o­gy, NanoCrys­tal. J&J an­nounced in 2021 that it was par­tial­ly ter­mi­nat­ing the two agree­ments, which it struck 1999 and 2003. How­ev­er, the ter­mi­na­tions of those agree­ments cut in­to roy­al­ty sales that Alk­er­mes re­ceives from Janssen’s schiz­o­phre­nia treat­ments, In­ve­ga Susten­na and In­ve­ga Trin­za. Ar­bi­tra­tion pro­ceed­ings start­ed in 2022.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER